drugset / Trial / NCT00259337
Immunogenicity and Safety of Pentaxim™ in an Indian Population
Non-randomizedSingle-groupOpen-labelPrevention
Summary
The present clinical study will assess the immunogenicity as the primary objective and the reactogenicity as the secondary objective of Aventis Pasteur's DTacP-IPV// PRP\~T combined vaccine (Pentavac™ or Pentaxim™) as a three-dose primary vaccination at 6, 10 and 14 weeks of age followed by a booster dose during the second year of life. Safety: This study will describe the safety after each dose of the primary series of the study's combined vaccine (Pentaxim™).
Timeline
- Start
- 2006-02
- Primary completion
- 2008-04
- Completion
- 2008-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | PENTAXIM™ | Vaccine | 0.5 ml | Intramuscular |